| abstract |
The use of an anti-CD73 antibody, or an antigen-binding fragment thereof, and an A2A receptor inhibitor for inhibiting tumor growth in a subject, increasing an anti-tumor immune response in a subject or for treating a tumor in a subject. Preferably, the anti-CD73 antibody is MEDI9447 or Phen0203 hIgG1 and the A2A receptor inhibitor is SCH58261. Also claimed are kits and pharmaceutical compositions comprising an anti-CD73 antibody and an A2A receptor inhibitor. |